Delivery of serotonin to the brain by monocytes following phagocytosis of liposomes

Journal of Controlled Release

Volumn 132, Issue 2, 2008, Pages 84-90

  Afergan, Eyal ^a   Epstein, Hila ^a   Dahan, Rachel ^a   Koroukhov, Nickolay ^a   Rohekar, Keren ^a   Danenberg, Haim D ^b   Golomb, Gershon ^a  

^a Faculty of Medicine   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Blood brain barrier; Brain transport; Drug delivery; Liposomes; monocytes; Neutrophils

Indexed keywords

ANIMAL CELL CULTURE; ANTIGEN-ANTIBODY REACTIONS; BLOOD; BODY FLUIDS; DRUG DELIVERY; IMMUNOLOGY; LIPOSOMES; PHOTOLITHOGRAPHY; RATS;

BIODISTRIBUTION; BRAIN DELIVERIES; FLUORESCENT MARKERS; IN VITRO; INNATE IMMUNE SYSTEMS; MONOCYTES; NEUTROPHILS; PHAGOCYTIC CELLS;

PHOSPHOLIPIDS;

LIPOSOME; SEROTONIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG TRANSPORT; DRUG UPTAKE; HUMAN; HUMAN CELL; MALE; MONOCYTE; NANOENCAPSULATION; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; RABBIT; RAT; SPRAGUE DAWLEY RAT;

ANIMALS; BRAIN; BRAIN CHEMISTRY; CELL MOVEMENT; CHOLESTEROL; DRUG DELIVERY SYSTEMS; ENDOCYTOSIS; HUMANS; INJECTIONS, INTRAVENOUS; LIPOSOMES; MALE; MONOCYTES; NEUTROPHILS; PHAGOCYTOSIS; PHOSPHATIDYLCHOLINES; PHOSPHATIDYLGLYCEROLS; RABBITS; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN; SEROTONIN AGENTS; TISSUE DISTRIBUTION;

EID: 56349113764     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2008.08.017     Document Type: Article

References (54)

1. Pardridge W.M. Drug targeting to the brain. Pharm. Res. 24 (2007) 1733-1734
2. Cornford E.M., and Hyman S. Blood-brain barrier permeability to small and large molecules. Adv. Drug Del. Rev. 36 (1999) 145-163
3. Bickel U., Yoshikawa T., and Pardridge W.M. Delivery of peptides and proteins through the blood-brain barrier. Adv. Drug Deliv. Rev. 46 1-3 (2001) 247-279
4. Bodor N., and Buchwald P. Recent advances in the brain targeting of neuropharmaceuticals by chemical delivery systems. Adv. Drug Deliv. Rev. 36 2-3 (1999) 229-254
5. Emerich D.F. Recent efforts to overcome the blood-brain barrier for drug delivery. Expert Opin. Ther. Patents 10 3 (2000) 279-287
6. Kreuter J., Shamenkov D., Petrov V., Ramge P., Cychutek K., Koch-Brandt C., and Alyautdin R. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J. Drug Targeting 10 (2002) 317-325
7. Umezawa F., and Eto Y. Liposome targeting to mouse brain: mannose as a recognition marker. Biochem. Biophys. Res. Commun. 153 3 (1988) 1038-1044
8. Schackert G., Fan D., Nayar R., and Fidler I.J. Arrest and retention of multilamellar liposomes in the brain of normal mice or mice bearing experimental brain metastases. Select. Cancer Ther. 5 2 (1989) 73-79
9. Rousseau V., Denizot B., Le Jeune J.J., and Jallet P. Early detection of liposome brain localization in rat experimental allergic encephalomyelitis. Exp. Brain Res. 125 3 (1999) 255-264
10. Omori N., Maruyama K., Jin G., Li F., Wang S.J., Hamakawa Y., Sato K., Nagano I., Shoji M., and Abe K. Targeting of post-ischemic cerebral endothelium in rat by liposomes bearing polyethylene glycol-coupled transferrin. Neurol. Res. 25 3 (2003) 275-279
11. Huwyler J., Wu D.F., and Pardridge W.M. Brain drug delivery of small molecules using immunoliposomes. Proc. Natl. Acad. Sci. 93 24 (1996) 14164-14169
12. Stavraky R.T., Grant C.W., Barber K.R., and Karlik S.J. Baseline consideration of liposomal contrast agent. CNS transport by macrophages in experimental allergic encephalomyelitis. Magn. Reson. Imaging 11 5 (1993) 685-689
13. Rousseau V., Denizot B., Pouliquen D., Jallet P., and Le Jeune J.J. Investigation of blood-brain barrier permeability to magnetite-dextran nanoparticles (MD3) after osmotic disruption in rats. Magma 5 3 (1997) 213-222
14. Troster S.D., Muller U., and Kreuter J. Modification of the body distribution of poly(methyl methacrylate) nanoparticles in rats by coating with surfactants. Int. J. Pharm. 61 (1990) 85-100
15. Schroeder U., Sommerfeld P., Ulrich S., and Sabel B.A. Nanoparticle technology for delivery of drugs across the blood-brain barrier. J. Pharm. Sci. 87 (1998) 1305-1307
16. Gulayev A.E., Gelperina S.E., Skidan I.N., Antropov A.S., Kivman G.Y., and Kreuter J. Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm. Res. 16 (1999) 1564-1569
17. Calvo P., Gouritin B., Chacun H., Desmaele D., D'Angelo J., Noel J.P., Georgin D., Fattal E., Andreux J.P., and Couvreur P. Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery. Pharm. Res. 18 8 (2001) 1157-1166
18. Kreuter J., Ramge P., Petrov V., Hamm S., Gelperina S.E., Engelhardt B., Alyautdin R., von Briesen H., and Begley D.J. Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles. Pharm. Res. 20 (2003) 409-416
19. Kim H.R., Gil S., Andrieux K., Nicolas V., Appel M., Chacun H., Desmaele D., Taran F., Georgin D., and Couvreur P. Low-density lipoprotein receptor-mediated endocytosis of PEGylated nanoparticles in rat brain endothelial cells. Cell Mol. Life Sci. 64 3 (2007) 356-364
20. Jallouli Y., Paillard A., Chang J., Sevin E., and Betbeder D. Influence of surface charge and inner composition of porous nanoparticles to cross blood-brain barrier in vitro. Int. J. Pharm. 344 (2007) 103-109
21. Olivier J.C., Fenart L., Chauvet R., Pariat C., Cecchelli R., and Couet W. Indirect evidence that drug brain targeting using polysorbate 80-coated polybutylcyanoacrylate nanoparticles is related to toxicity. Pharm. Res. 16 12 (1999) 1836-1842
22. Lockman P.R., Koziara J., Roder K.E., Paulson J., Abbruscato T.J., Mumper R.J., and Allen D.D. In vivo and in vitro assessment of baseline blood-brain barrier parameters in the presence of novel nanoparticles. Pharm. Res. 20 5 (2003) 705-713
23. Harris J.P., and Ryan A.F. Fundamental immune mechanisms of the brain and inner ear. Otolaryngol. Head Neck Surg. 112 6 (1995) 639-653
24. Miller D.W. Immunobiology of the blood-brain barrier. J. Neurovirol. 5 6 (1999) 570-578
25. Hickey W.F., Hsu B.L., and Kimura H. T-lymphocyte entry into the central nervous system. J. Neurosci. Res. 28 2 (1991) 254-260
26. Andersson P.B., Perry V.H., and Gordon S. Intracerebral injection of proinflammatory cytokines or leukocyte chemotaxins induces minimal myelomonocytic cell recruitment to the parenchyma of the central nervous system. J. Exp. Med. 176 1 (1992) 255-259
27. Nottet H.S., Persidsky Y., Sasseville V.G., Nukuna A.N., Bock P., Zhai Q.H., Sharer L.R., McComb R.D., Swindells S., Soderland C., and Gendelman H.E. Mechanisms for the transendothelial migration of HIV-1-infected monocytes into brain. J. Immunol. 156 3 (1996) 1284-1295
28. Knopf P.M., Harling-Berg C.J., Cserr H.F., Basu D., Sirulnick E.J., Nolan S.C., Park J.T., Keir G., Thompson E.J., and Hickey W.F. Antigen-dependent intrathecal antibody synthesis in the normal rat brain: tissue entry and local retention of antigen-specific B cells. J. Immunol. 161 2 (1998) 692-701
29. Persidsky Y. Model systems for studies of leukocyte migration across the blood-brain barrier. J. Neurovirol. 5 (1999) 579-590
30. Schroit A.J., Madsen J., and Nayar R. Liposome-cell interactions: in vitro discrimination of uptake mechanism and in vivo targeting strategies to mononuclear phagocytes. Chem. Phys. Lipids 40 2-4 (1986) 373-393
31. van Rooijen N., and Sanders A. Elimination, blocking, and activation of macrophages: three of a kind?. J. Leukoc. Biol. 62 6 (1997) 702-709
32. Patel H.M., and Moghimi S.M. Serum-mediated recognition of liposomes by phagocytic cells of the reticuloendothelial system - the concept of tissue specificity. Adv. Drug Deliv. Rev. 32 1-2 (1998) 45-60
33. Moghimi S., Hunter A., and Murray J. Long-circulating and target-specific nanoparticles: theory to practice. Pharmcol. Rev. 53 (2001) 283-318
34. Ahsan F.L., Rivas I.P., Khan M.A., and Suarez A.I.T. Targeting to macrophages: role of physicochemical properties of particulate carriers-liposomes and microspheres-on the phagocytosis by macrophages. J. Controlled Rel. 79 1-3 (2002) 29-40
35. Danenberg H.D., Fishbein I., Gao J., Monkkonen J., Reich R., Gati I., Moerman E., and Golomb G. Macrophage depletion by clodronate-containing liposomes reduces neointimal formation after balloon injury in rats and rabbits. Circulation 106 5 (2002) 599-605
36. Danenberg H.D., Fishbein I., Epstein H., Waltenberger J., Moerman E., Monkkonen J., Gao J., Gathi I., Reichi R., and Golomb G. Systemic depletion of macrophages by liposomal bisphosphonates reduces neointimal formation following balloon-injury in the rat carotid artery. J. Cardiovasc Pharmacol. 42 5 (2003) 671-679
37. Danenberg H.D., Golomb G., Groothuis A., Gao J., Epstein H., Swaminathan R.V., Seifert P., and Edelman E.R. Liposomal alendronate inhibits systemic innate immunity and reduces in-stent neointimal hyperplasia in rabbits. Circulation 108 22 (2003) 2798-2804
38. Raz A., Bucana C., Fogler W.E., Poste G., and Fidler I.J. Biochemical, morphological, and ultrastructural studies on the uptake of liposomes by murine macrophages. Cancer Res. 41 2 (1981) 487-494
39. Sato Y., Kiwada H., and Kato Y. Effects of dose and vesicle size on the pharmacokinetics of liposomes. Chem. Pharm. Bull. (Tokyo) 34 10 (1986) 4244-4252
40. Patel H.M. Serum opsonins and liposomes: their interaction and opsonophagocytosis. Crit. Rev. Ther. Drug Carrier Syst. 9 1 (1992) 39-90
41. Udenfriend S., Weissbach H., and Bogdanski D.F. Increase in tissue serotonin following administration of its precursor 5-hydroxytryptophan. J. Biol. Chem. 224 2 (1957) 803-810
42. Szoka Jr. F., and Papahadjopoulos D. Comparative properties and methods of preparation of lipid vesicles (liposomes). Ann. Rev. Biophys. Bioeng. 9 (1980) 467-508
43. Epstein H., Berger V., Levi I., Eisenberg G., Koroukhov N., Gao J., and Golomb G. Nanosuspensions of alendronate with gallium or gadolinium attenuate neointimal hyperplasia in rats. J. Controlled Rel. 117 3 (2007) 322-332
44. Rodrigueza W.V., Pritchard P.H., and Hope M.J. The influence of size and composition on the cholesterol mobilizing properties of liposomes in vivo. Biochim. Biophys. Acta 1153 1 (1993) 9-19
45. Kao Y.J., and Juliano R.L. Interactions of liposomes with the reticuloendothelial system: effects of reticuloendothelial blockade on the clearance of large unilamellar vesicles. Biochim. Biophys. Acta 677 3-4 (1981) 453-461
46. Huitinga I., van Rooijen N., de Groot C.J., Uitdehaag B.M., and Dijkstra C.D. Suppression of experimental allergic encephalomyelitis in Lewis rats after elimination of macrophages. J. Exp. Med. 172 4 (1990) 1025-1033
47. Huitinga I., Ruuls S.R., Jung S., Van Rooijen N., Hartung H.P., and Dijkstra C.D. Macrophages in T cell line-mediated, demyelinating, and chronic relapsing experimental autoimmune encephalomyelitis in Lewis rats. Clin. Exp. Immunol. 100 2 (1995) 344-351
48. Gregoriadis G. Liposomes as a drug delivery system: optimization studies. Adv. Exp. Med. Biol. 238 (1988) 151-159
49. Buiting A.M., de Rover Z., Claassen E., and van Rooijen N. In vivo distribution of particulate antigens and liposomes in murine spleen. A possible role in the humoral immune response. Immunobiology 188 1-2 (1993) 13-22
50. Carlos T.M., and Harlan J.M. Leukocyte-endothelial adhesion molecules. Blood 84 7 (1994) 2068-2101
51. Pakianathan D.R. Extracellular matrix proteins and leukocyte function. J. Leukoc. Biol. 57 5 (1995) 699-702
52. Cross A.H., and Raine C.S. Central nervous system endothelial cell-polymorphonuclear cell interactions during autoimmune demyelination. Am. J. Pathol. 139 6 (1991) 1401-1409
53. Oliver A.R., Lyon G.M., and Ruddle N.H. Rat and human myelin oligodendrocyte glycoproteins induce experimental autoimmune encephalomyelitis by different mechanisms in C57BL/6 mice. J. Immunol. 171 1 (2003) 462-468
54. Dickstein D.L., Biron K.E., Ujiie M., Pfeifer C.G., Jeffries A.R., and Jefferies W.A. A β peptide immunization restores blood-brain barrier integrity in Alzheimer disease. FASEB J. 20 3 (2006) 426-433